Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
打开标签
医学
开放标签研究
标签外使用
内科学
儿科
临床试验
不利影响
作者
Antonio M. Risitano,Austin Kulasekararaj,Phillip Scheinberg,Alexander Röth,Bing Han,Jaroslaw P. Maciejewski,Yasutaka Ueda,Carlos M. de Castro,Eros Di Bona,Rong Fu,Zhang Li,Morag Griffin,Saskia Langemeijer,Jens Panse,Hubert Schrezenmeier,Wilma Barcellini,Vitor AQ Mauad,Philippe Schafhausen,Suzanne Tavitian,Eloise Beggiato